BNTX — BioNTech SE Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for BioNTech SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	20-F	20-F	20-F	20-F	20-F
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	482	18,977	17,311	3,819	2,751
Cost of Revenue
Gross Profit	423	16,065	14,316	3,219	2,336
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	565	3,693	4,668	3,129	4,065
Operating Profit	-82.4	15,284	12,643	690	-1,314
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-146	15,046	12,954	1,186	-678
Provision for Income Taxes
Net Income After Taxes	15.2	10,293	9,434	930	-665
Minority Interest
Net Income Before Extraordinary Items
Net Income	15.2	10,293	9,434	930	-665
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	15.2	10,293	9,434	930	-665
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.06	39.3	37.8	3.95	-2.21
Special Dividends per Share